New Phone Number for the Maternal Mental Health Hotline: 1-833-TLC-MAMA
This hotline will offer a range of support, including brief interventions, referrals to both community-based and telehealth providers as needed.
Can We Use Machine Learning to Predict Risk for Perinatal Depression?
Imagine if we could use machine learning to enhance the care we deliver, analyzing a larger body of patient-specific factors in order to make more reliable predictions of risk for perinatal mood and anxiety disorders.
Sleep Disturbance and Suicidal Ideation in Pregnant and Postpartum Women
Addressing sleep problems may be an important component of suicide prevention efforts, as improving sleep quality and duration may help to reduce the risk of suicide in perinatal population.
Coach-Supported Web-Based Intervention for Mild to Moderate Postpartum Depression
This preliminary study suggests that web-based interventions with coaching are feasible, acceptable, and potentially effective treatment options for women with mild to moderate postpartum depression and/or anxiety.
Single Day CBT-Based Workshops for Mothers with Postpartum Depression
In this randomized controlled trial, a CBT-based workshop for women with PPD led to clinically meaningful reductions in depression and anxiety.
Zuranolone Improves Anxiety Symptoms and Insomnia in Women with Postpartum Depression
In women with postpartum depression, zuranolone was associated with concurrent improvements in depression, anxiety symptoms, and insomnia beginning at day 3.
Sleep Disturbance During Pregnancy and Risk for Perinatal Depression
Evidence suggests that sleep disturbance during pregnancy is associated with higher risk of perinatal depression, especially during the third trimester.
When a New Baby Comes Home, Do Moms and Dads Get Depressed Together?
Should we also be assessing women’s partners to determine if they have postpartum depression?
Canadian Task Force recommendation on screening for postpartum depression misses the mark
Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on the new recommendation by the Canadian Task Force on Preventative Health Care which advises against systematic questionnaires for PPD screening with Ob.Gyn News on January 20, 2023.
Zuranolone: Novel, Rapid-Acting Antidepressant Awaits FDA Approval
A New Drug Application for zuranolone awaits FDA approval for the treatment of major depressive disorder (MDD) and postpartum depression (PPD).